Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126488171 | 12648817 | 1 | I | 2016 | 20160808 | 20160812 | 20160812 | PER | US-PFIZER INC-2016381739 | PFIZER | 49.00 | YR | F | Y | 57.14000 | KG | 20160812 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126488171 | 12648817 | 1 | PS | IBRANCE | PALBOCICLIB | 1 | Oral | 125 MG, CYCLIC, (DAILY FOR 21 DAYS FOLLOWED BY 7 DAYS REST PERIOD BEFORE BEGINING A, NEW CYCLE) | 207103 | 125 | MG | CAPSULE | |||||||
| 126488171 | 12648817 | 2 | SS | FASLODEX | FULVESTRANT | 1 | Intramuscular | UNK | U | 0 | |||||||||
| 126488171 | 12648817 | 3 | C | CALCIUM D | CALCIUMVITAMIN D | 1 | Oral | 1 DF, 2X/DAY | 0 | 1 | DF | TABLET | BID | ||||||
| 126488171 | 12648817 | 4 | C | CARAFATE | SUCRALFATE | 1 | Oral | 1 G, 4X/DAY (15 DAYS) | 0 | 1 | G | TABLET | QID | ||||||
| 126488171 | 12648817 | 5 | C | ERGOCALCIFEROL. | ERGOCALCIFEROL | 1 | Oral | 50000 IU, WEEKLY | 0 | 50000 | IU | CAPSULE | /wk | ||||||
| 126488171 | 12648817 | 6 | C | FOLIC ACID. | FOLIC ACID | 1 | Oral | 1 MG, DAILY | 0 | 1 | MG | TABLET | |||||||
| 126488171 | 12648817 | 7 | C | LIDODERM | LIDOCAINE | 1 | Transdermal | 5 %, AS NEEDED | 0 | 5 | PCT | ||||||||
| 126488171 | 12648817 | 8 | C | LIDODERM | LIDOCAINE | 1 | 0 | ||||||||||||
| 126488171 | 12648817 | 9 | C | LORAZEPAM. | LORAZEPAM | 1 | Oral | 0.5 MG, AS NEEDED (TWICE A DAY) | 0 | .5 | MG | TABLET | |||||||
| 126488171 | 12648817 | 10 | C | LORAZEPAM. | LORAZEPAM | 1 | 0 | TABLET | |||||||||||
| 126488171 | 12648817 | 11 | C | LORAZEPAM. | LORAZEPAM | 1 | 0 | TABLET | |||||||||||
| 126488171 | 12648817 | 12 | C | LUPRON DEPOT-PED | LEUPROLIDE ACETATE | 1 | Intramuscular | 7.5 MG, MONTHLY | 0 | 7.5 | MG | /month | |||||||
| 126488171 | 12648817 | 13 | C | MAGNESIUM OXIDE. | MAGNESIUM OXIDE | 1 | Oral | 500 MG, DAILY | 0 | 500 | MG | TABLET | |||||||
| 126488171 | 12648817 | 14 | C | METHOTREXATE. | METHOTREXATE | 1 | Oral | 25 MG (2.5 MG TABLET TAKE 10), WEEKLY | 0 | 25 | MG | TABLET | /wk | ||||||
| 126488171 | 12648817 | 15 | C | ONDANSETRON HCL | ONDANSETRON HYDROCHLORIDE | 1 | Oral | 8 MG, 3X/DAY (EVERY 8 HOURS X 30 DAYS) | 0 | 8 | MG | TABLET | TID | ||||||
| 126488171 | 12648817 | 16 | C | OXYCODONE | OXYCODONE | 1 | Oral | 5 MG, AS NEEDED (EVERY 4 HOURS X 15 DAYS) | 0 | 5 | MG | TABLET | |||||||
| 126488171 | 12648817 | 17 | C | PRILOSEC | OMEPRAZOLE MAGNESIUM | 1 | Oral | 40 MG (20 MG CAPSULE DR TAKE 2), 1X/DAY (EVERY MORNING) | 0 | 40 | MG | PROLONGED-RELEASE CAPSULE | QD | ||||||
| 126488171 | 12648817 | 18 | C | REMICADE | INFLIXIMAB | 1 | Intravenous drip | UNK (ONE TIME, EVERY 8 WEEKS) | 0 | ||||||||||
| 126488171 | 12648817 | 19 | C | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | Oral | 25 MG, DAILY | 0 | 25 | MG | TABLET | |||||||
| 126488171 | 12648817 | 20 | C | VITAMIN B12 | CYANOCOBALAMIN | 1 | Intramuscular | 1000 UG/ML, MONTHLY (DISPENSE ONE 10 ML VIAL) | 0 | /month | |||||||||
| 126488171 | 12648817 | 21 | C | VITAMIN B6 | PYRIDOXINE HYDROCHLORIDE | 1 | Oral | 1 DF, DAILY | 0 | 1 | DF | ||||||||
| 126488171 | 12648817 | 22 | C | VITAMIN D3 | CHOLECALCIFEROL | 1 | Oral | 1000 IU, 1X/DAY (EVERY 24 HOURS, AFTER 12 WEEKS) | 0 | 1000 | IU | TABLET | QD | ||||||
| 126488171 | 12648817 | 23 | C | WARFARIN SODIUM. | WARFARIN SODIUM | 1 | Oral | 4 MG, AS NEEDED (QPM) | 0 | 4 | MG | TABLET | |||||||
| 126488171 | 12648817 | 24 | C | WARFARIN SODIUM. | WARFARIN SODIUM | 1 | Oral | 1 MG, UNK | 0 | 1 | MG | TABLET | |||||||
| 126488171 | 12648817 | 25 | C | ZOMETA | ZOLEDRONIC ACID | 1 | Intravenous drip | 4 MG (4 MG/5 ML VIAL TAKE 5 ML), NK IV INFUSION 3QMONTH | 0 | 4 | MG | ||||||||
| 126488171 | 12648817 | 26 | C | INJECTAFER | FERRIC CARBOXYMALTOSE | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126488171 | 12648817 | 1 | Breast cancer metastatic |
| 126488171 | 12648817 | 2 | Breast cancer metastatic |
| 126488171 | 12648817 | 7 | Pain |
| 126488171 | 12648817 | 8 | Back pain |
| 126488171 | 12648817 | 9 | Nausea |
| 126488171 | 12648817 | 10 | Anxiety |
| 126488171 | 12648817 | 11 | Sleep disorder |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126488171 | 12648817 | Off label use | |
| 126488171 | 12648817 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126488171 | 12648817 | 1 | 20160516 | 0 | ||
| 126488171 | 12648817 | 2 | 20160517 | 0 | ||
| 126488171 | 12648817 | 22 | 20160530 | 0 | ||
| 126488171 | 12648817 | 25 | 20120209 | 0 |